Effient Related Clinical Trials
A Study of Prasugrel in Healthy Participants [Completed]
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease [Completed]
A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet [Completed]
Prasugrel With Lower Dose - Loading Dose [Completed]
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients [Completed]
Prasugrel Versus Clopidogrel to TREAT High Platelet Reactivity [Completed]
Study of Prasugrel in Korean Healthy Male Volunteers [Completed]
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease [Completed]
Prasugrel/Clopidogrel Maintenance Dose Washout Study [Completed]
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease [Completed]
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor [Recruiting]
Pharmacological Effects of Crushing Prasugrel in STEMI Patients [Recruiting]
An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults [Completed]
Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event [Completed]
Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease [Completed]
Cangrelor Prasugrel Transition Study [Completed]
Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases III Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST III Trial - REDUCE POLYTECH RCT) [Not yet recruiting]
Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction [Terminated]
PRAsugrel or clopIdogrel in Acute Coronary SyndromE Patients With CYP2C19 Polymorphism Before Percutaneous Coronary Intervention [Recruiting]
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes [Recruiting]
The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS) [Completed]
Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis [Recruiting]
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI) [Completed]
Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction [Active, not recruiting]
Prasugrel Versus Placebo in Adult Sickle Cell Disease [Completed]
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function: [Recruiting]
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention [Completed]
Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation [Completed]
Ticagrelor vs. Prasugrel Effects on Infarct Size [Not yet recruiting]
High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients [Completed]
Prasugrel Re-load Strategies [Completed]
Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial [Completed]
Plavix, Prasugrel and Drug Eluting Stents Pilot Trial [Recruiting]
PhaRmacodynamic Effect of Therapy With PraSugrel or TicagrElor in Acute Coronary Syndrome paTients With Diabetes Mellitus [Not yet recruiting]
High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) [Completed]
Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention [Completed]
Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel [Recruiting]
The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel [Active, not recruiting]
Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome [Not yet recruiting]
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD) [Active, not recruiting]
Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing [Recruiting]
BLeeding Events and Maintenance DoSe of PraSugrel [Recruiting]
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease [Completed]
Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting [Completed]
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease [Completed]
Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) [Terminated]
Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI [Not yet recruiting]
Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis [Completed]
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes [Terminated]
Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment [Completed]
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis [Completed]
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI). [Completed]
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel [Completed]
PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males [Completed]
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) [Completed]
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI [Completed]
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3) [Completed]
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome [Recruiting]
Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial [Recruiting]
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin) [Recruiting]
High "on Treatment" Platelet Reactivity in the Intensive Care Unit [Recruiting]
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor [Recruiting]
Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome [Completed]
Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome [Recruiting]
Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease [Recruiting]
Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers [Recruiting]
Time to Thrombocytic Inhibition After Supine and Upright Ingestion of Efient [Active, not recruiting]
A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome [Completed]
Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse [Completed]
Cangrelor to Clopidogrel or Prasugrel Transition Study [Completed]
Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention [Completed]
The Elderly ACS II Trial [Recruiting]
The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma [Completed]
The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation [Completed]
Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST) [Recruiting]
XIENCE V� USA Dual Antiplatelet Therapy (DAPT) Cohort [Completed]
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study) [Recruiting]
A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk [Recruiting]
Identification of Clopidogrel CYP2C19 Metabolizer and Thienopyridine Treatment After an Acute Coronary Syndrome [Completed]
P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI [Enrolling by invitation]
Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent [Recruiting]
African-American Pharmacogenetics [Active, not recruiting]
FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization. [Active, not recruiting]
REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux. [Completed]
Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease [Completed]
"Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy" [Recruiting]
Customized Choice of Oral P2Y12 Receptor Blocker [Recruiting]
Potential Impact of Cigarette Smoking on Platelet Reactivity in Patients on Dual Antiplatelet Therapy With P2Y12 Inhibitors [Recruiting]
Xience Versus Synergy in Left Main PCI [Not yet recruiting]
Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study [Completed]
Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. [Not yet recruiting]
|